Placental abruption screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 4: | Line 4: | ||
==screeninig== | ==screeninig== | ||
*First trimester (pregnancy-associated placental protein-A [PAPP-A]) | *First trimester (pregnancy-associated placental protein-A [PAPP-A]) | ||
*second trimester (total hCG and alpha fetoprotein [AFP]) serum biochemistry were determined.The two screening periods were compared for the prediction of a range of severe adverse perinatal outcomes (intrauterine growth restriction [IUGR], abruption, severe pre-eclampsia/HELLP syndrome, delivery < 32 weeks, or stillbirth). | *second trimester (total hCG and alpha fetoprotein [AFP]) serum biochemistry were determined.The two screening periods were compared for the prediction of a range of severe adverse perinatal outcomes (intrauterine growth restriction [IUGR], abruption, severe pre-eclampsia/HELLP syndrome, delivery < 32 weeks, or stillbirth).<ref name="pmid28178056">{{cite journal| author=Ananth CV, Wapner RJ, Ananth S, DʼAlton ME, Vintzileos AM| title=First-Trimester and Second-Trimester Maternal Serum Biomarkers as Predictors of Placental Abruption. | journal=Obstet Gynecol | year= 2017 | volume= 129 | issue= 3 | pages= 465-472 | pmid=28178056 | doi=10.1097/AOG.0000000000001889 | pmc=5367463 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28178056 }}</ref> | ||
*MRI is a complementary technique that should be considered when ultrasound is inconclusive or incomplete. | *MRI is a complementary technique that should be considered when ultrasound is inconclusive or incomplete.<ref name="pmid22268173">{{cite journal| author=Leyendecker JR, DuBose M, Hosseinzadeh K, Stone R, Gianini J, Childs DD | display-authors=etal| title=MRI of pregnancy-related issues: abnormal placentation. | journal=AJR Am J Roentgenol | year= 2012 | volume= 198 | issue= 2 | pages= 311-20 | pmid=22268173 | doi=10.2214/AJR.11.7957 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22268173 }}</ref> | ||
== References == | == References == | ||
Latest revision as of 15:27, 3 August 2020
|
Placental abruption Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Placental abruption screening On the Web |
|
American Roentgen Ray Society Images of Placental abruption screening |
|
Risk calculators and risk factors for Placental abruption screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief:Rana aljebzi, M.D.[2]
screeninig
- First trimester (pregnancy-associated placental protein-A [PAPP-A])
- second trimester (total hCG and alpha fetoprotein [AFP]) serum biochemistry were determined.The two screening periods were compared for the prediction of a range of severe adverse perinatal outcomes (intrauterine growth restriction [IUGR], abruption, severe pre-eclampsia/HELLP syndrome, delivery < 32 weeks, or stillbirth).[1]
- MRI is a complementary technique that should be considered when ultrasound is inconclusive or incomplete.[2]
References
- ↑ Ananth CV, Wapner RJ, Ananth S, DʼAlton ME, Vintzileos AM (2017). "First-Trimester and Second-Trimester Maternal Serum Biomarkers as Predictors of Placental Abruption". Obstet Gynecol. 129 (3): 465–472. doi:10.1097/AOG.0000000000001889. PMC 5367463. PMID 28178056.
- ↑ Leyendecker JR, DuBose M, Hosseinzadeh K, Stone R, Gianini J, Childs DD; et al. (2012). "MRI of pregnancy-related issues: abnormal placentation". AJR Am J Roentgenol. 198 (2): 311–20. doi:10.2214/AJR.11.7957. PMID 22268173.